Attached files

file filename
EX-99.1 - WaferGen Bio-systems, Inc.ex_99-1.htm


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 14, 2013


 
WaferGen Bio-systems, Inc.
 
 
(Exact name of registrant as specified in its charter)
 

 
Nevada
 
000-53252
 
90-0416683
 
 
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
 

 
7400 Paseo Padre Parkway, FremontCA
 
94555
 
 
(Address of principal executive offices)
 
(Zip Code)
 

(Registrant’s telephone number, including area code):  (510) 651-4450

Not Applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 





 
 

 

Item 2.02.  Results of Operations and Financial Condition.

On November 14, 2013, WaferGen Bio-systems, Inc. issued a press release announcing its financial results for the third quarter of the year ending December 31, 2013. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.


Item 9.01.  Financial Statements and Exhibits.

(d)        Exhibits.

Exhibit No.
 
Description
99.1
 
Press release issued on November 14, 2013




 
 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
WaferGen Bio-systems, Inc.
 
 
 
 
Date: November 14, 2013
By:
/s/ JOHN HARLAND
 
   
John Harland
 
   
Chief Financial Officer
 



 
 

 

EXHIBIT INDEX
 
Exhibit No.
 
Description
99.1
 
Press release issued on November 14, 2013